Merck not only loses hep C case against Gilead, it gets stuck with the bill

Justice statue with sword and scales

Merck & Co. was sitting pretty earlier this year after winning a legal dispute over sofosbuvir, the active ingredient in Gilead's multibillion-dollar babies Sovaldi and Harvoni. But all of that turned around when a judge threw out the victory and snatched back the $200 million Merck had been awarded. Now, to add insult to injury, Merck has been handed a $200 million bill for Gilead’s legal fees.

In a filing on Thursday, U.S. District Judge Beth Labson Freeman said that Gilead was entitled to relief from the fees it incurred while defending the case, Reuters reports.

Merck had won the case in March, but then in June, Labson Freeman reversed the decision, saying she found “a pervasive pattern of misconduct” by Merck ($MRK) in the patent fight. A retired Merck scientist and lawyer “intentionally fabricated testimony” about early discoveries that led to the development of next-generation hepatitis C drugs, including Gilead’s blockbuster duo, Harvoni and Sovaldi, the ruling states. And Merck supported the “bad faith conduct,” the judge said.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Merck, which has trailed Gilead in the lucrative hep C market, had hoped to capture a piece of Gilead’s enormous revenue stream from Harvoni and Sovaldi. The earlier jury verdict delivered only a $200 million award but also opened the way for Merck to pursue royalties from the two blockbuster drugs’ ongoing sales. Merck’s rival hep C cocktail, Zepatier, recently won FDA approval, but Gilead’s meds have an enormous head start in the market, with more than $23 billion in combined sales since their launches.

Merck said earlier that it intended to appeal, saying the judge’s ruling “does not reflect the facts of the case.”

- read the Reuters story

Related Articles:
Judge nixes Merck's $200M hep C patent win, citing 'fabricated' testimony, 'pervasive' misconduct 
Merck wins first round in $3B-plus hep C royalty fight with Gilead 
Merck's $200M damages in Gilead hep C case falls far short of expectations
Judge nixes Merck's $200M hep C patent win, citing 'fabricated' testimony, 'pervasive' misconduct

Read more on

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.